Highlights in therapy-related myeloid neoplasms
Organizers: MT Voso, K Döhner, R Dillon, MK Yuksel, N Ghahramanyan, D Capone
Aula Francesco Mandelli – AIL Headquarters, Rome, Italy, 9th and 10th February, 2023
Among cancer survivors, the incidence of therapy-related myeloid neoplasms (t-MN) definitely calls for urgent action: although it is rare in the general population, one of 200 breast cancer patients, one of 10 patients treated for non-Hodgkin lymphoma and up to 1.0% of children treated for hematological, solid and central nervous system cancers develop t-MN.
Prompted by a story of positive interaction between NAnA an energetic small Patient Advocacy Organization (PAO) and the European research group led by Prof. MT Voso at University of Tor Vergata (Rome), the workshop will focus on t-MN scientific knowledge and tools for the recognition and clinical management of t-MN, with the aim of creating a constructive debate for innovative point-of-views and essential advancements in the field.
Skilled European researchers will gather in Rome to discuss prevention and cure t-MN development, investigating the type and dosage of cancer therapy, aging process, inherited and environmental risk factors and genetic abnormalities in haematopoietic stem cells. Discussions will converge on a Research and Innovation Agenda regarding t-MN, with a dual focus on translation from research to the bed side and industry as well as a on health-related quality of life (HRQOL) for cancer survivors. Representatives of European Patient Advocacy Organizations and industry are invited at the Round table “The patient social point of view”.
4 abstracts by early career scientists (below the age of 40) will be selected for oral presentation at the workshop. Deadline for abstract submission is December 15, 2022. A few travel and lodging grants will be available.
This workshop is funded by the European Joint Programme on Rare Diseases. Registration is required. The Abstract book will be available online to all registered participants.